SAI Parenteral’s Ltd (SPL), a diversified pharmaceutical formulation company, has acquired 74.6 per cent stake in Noumed Pharmaceuticals Pty Ltd, an Adelaide (Australia) -based pharmaceutical company, for ₹125 crore.
Noumed Pharmaceuticals, a company with AU$60 million in revenue, is a supplier of private label over the counter (OTC) products to pharmacy chains across Australia and New Zealand. The company is currently establishing a state-of-the-art manufacturing facility in Adelaide with an investment of AU$53 million which is expected to begin commercial operations by the fourth quarter of CY 2026. With a portfolio of over 451 product dossiers, Noumed is present across therapeutic categories.
“This acquisition marks a pivotal and transformative milestone in our journey towards becoming a global, innovation-led formulations and CDMO platform. By combining Noumed’s R&D capabilities, distribution network, extensive dossier library and upcoming manufacturing facility, along with SAI Parenterals’ strengths and capabilities in India, we are unlocking significant synergies across the value chain,’’ Anil KK, Managing Director, SAI Parenteral’s said in a release.
Mark Thulborne, Managing Director, Noumed Pharmaceuticals said: “Having worked with SAI Parenteral’s for a considerable time, we are confident that together we can accelerate our product pipeline, benefit from SAI’s manufacturing capabilities, and meet growing demand in the Australian, New Zealand, and global markets.’’
The Hyderabad-based SAI Parenteral’s is backed by marquee investors, including Samarsh Capital, Vyom Partners, Blue Lotus Capital and Gruhas. It has also filed its IPO DRHP with SEBI on September 30, 2025. The offer, with a face value of ₹5 per equity share, comprises a fresh issue of up to ₹285 crore and an offer for sale of up to 35 lakh equity shares by existing shareholders.